There are 2789 resources available
974P - Genetic and molecular analysis of solid tumors with hyperprogressive disease after treatment with immunotherapy
Presenter: Daniel Trotier
Session: ePoster Display
975P - Impact of body mass index on the efficacy of immune checkpoint inhibitors in cancer
Presenter: Alejandro Rios Hoyo
Session: ePoster Display
937P - Multicenter phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD
Presenter: Masafumi Ikeda
Session: ePoster Display
1202P - ALK-2016-CPHG: French cohort of advanced non-small cell lung cancer (aNSCLC) with ALK (ALK+) or ROS1 (ROS1+) gene rearrangement treated by crizotinib
Presenter: Didier Debieuvre
Session: ePoster Display
1203P - The analysis of ALK fusion variants in 4991 EGFR/MET mutation-negative non-squamous non-small cell lung carcinomas (NSCLCs)
Presenter: Evgeny Imyanitov
Session: ePoster Display
1204P - Cost-benefit analysis of ALK diagnosis in patients with non-small cell lung cancer in Spain
Presenter: Ana Laura Ortega Granados
Session: ePoster Display
1205P - Treatment sequencing and duration of subsequent tyrosine kinase inhibitors in ALK+ non-small cell lung cancer patients treated with brigatinib in the US
Presenter: Mohammad Jahanzeb
Session: ePoster Display
1206P - UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)
Presenter: Jair Bar
Session: ePoster Display
1169TiP - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: A phase II clinical study (ALTER-L043)
Presenter: Changli Wang
Session: ePoster Display